Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY),...
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongoing CAMBRIDGE, Mas...
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercialization expertise, to the Company’s Board of Directors Approximately $596 million in cash, cash equivalents and investments at end of Q3 2025 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changin...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in November: Guggenheim’s 2nd Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 11:00-11:25 a.m. ETJefferies 2025 Global Healthcare Conference on Wednesday, November 19, 2025 at 11...
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 6, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.